The impact of drying method and formulation on the physical properties and stability of methionyl human growth hormone in the amorphous solid state

Journal of Pharmaceutical Sciences

Volumn 97, Issue 1, 2008, Pages 163-184

  Abdul Fattah, Ahmad M ^a,c   Lechuga Ballesteros, David ^b   Kalonia, Devendra S ^a   Pikal, Michael J ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b NEKTAR THERAPEUTICS   (United States)

^c AMGEN INC   (United States)

Author keywords

Composition heterogeneity; Electron spectroscopy for chemical analysis (ESCA); Film drying; Freeze drying; Glass transition temperature (Tg); Human growth hormone (hGH); Particle morphology; Protein aggregation; Spray drying

Indexed keywords

DEXTRAN 40; EXCIPIENT; FICOLL; POLYMER; SOMATREM; SURFACTANT; TREHALOSE;

ARTICLE; CHEMICAL ANALYSIS; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG STABILITY; FREEZE DRYING; GLASS TRANSITION TEMPERATURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFRARED SPECTROSCOPY; MOLECULAR WEIGHT; PHYSICAL CHEMISTRY; PROTEIN SECONDARY STRUCTURE; SCANNING ELECTROCHEMICAL MICROSCOPY; SOLID STATE; SPRAY DRYING; SURFACE TENSION; THERMAL ANALYSIS;

EID: 38349150992     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21085     Document Type: Article

References (73)

1. Carpenter JF, Pikal MJ, Randolph TW. 1997. Rational design of stable lyophilized protein formulations: Some practical advice. Pharm Res 14:969-975.
2. Carpenter JF, Chang BS, Garzon-Rodriguez W, Randolph TW. 2002. Rational design of stable lyophilized protein formulations: Theory and practice. Pharm Biotechnol 13:109-133.
3. Costantino HR, Pikal MJ, editors. 2004. Lyophilization of biopharmaceuticals. [In: Biotechnol., Pharm. Aspects; 2004, 2].
4. Maaand Y-F, Prestrelski SJ. 2000. Biopharmaceutical powders: Particle formation and formulation considerations. Curr Pharm Biotechnol 1:283-302.
5. Lee G. 2002. Spray-drying of proteins. Pharm Biotechnol 13:135-158.
6. Maa Y-F, Ameri M, Chen D. 2004. Spray-coating for biopharmaceutical powder formulations: Beyond the conventional scale and its application. Pharm Res 21:515-523.
7. Jovanovic N, Bouchard A, Jiskoot W. 2004. Stabilization of proteins in dry powder formulations using supercritical fluid technology. Pharm Res 21:1955-1969.
8. Maa Y-F, Nguyen P-A, Hsu CC. 1999. Protein inhalation powders: Spray drying vs spray freeze drying. Pharm Res 16:249-254.
9. Webb SD, Golledge SL, Cleland JL, Carpenter JF, Randolph TW. 2002. Surface adsorption of recombinant human interferon-g in lyophilized and spray-lyophilized formulations. J Pharm Sci 91:1474-1487.
10. Bosquillon C, Rouxhet PG, Vanbever R. 2004. Aerosolization properties, surface composition and physical state of spray-dried protein powders. J Control Release 99:357-367.
11. Millqvist-Fureby A, Malmsten M, Bergenstahl B. 1999. Surface characterization and activity preservation in spray-drying of trypsin. Int J Pharm 188:243-253.
12. Maa Y-F, Ameri M, Chen D. 2004. Influenza vaccine powder formulation development: Spray-freeze-drying and stability evaluation. J Pharm Sci 93:1912-1923.
13. Adlerand M, Lee G. 1999. Stability and surface activity of lactate dehydrogenase in spray-dried trehalose. J Pharm Sci 88:199-208.
14. Adler M, Unger M, Lee G. 2000. Surface composition of spray-dried particles of bovine serum albumin/trehalose/surfactant. Pharm Res 17:863-870.
15. Faeldtand P, Bergenstahl B. 1994. The surface composition of spray-dried protein-lactose powders. Colloids Surf A: Physicochemical Eng Aspects 90:183-190.
16. Faeldt P, Bergenstahl B, Carlsson G. 1993. The surface coverage of fat on food powders analyzed by ESCA (electron spectroscopy for chemical analysis). Food Structure 12:225-234.
17. Millqvist-Fureby A, Burns N, Bergenstahl B. 1999. Surface activity at the air-water interface in relation to surface composition of spray-dried milk protein-stabilized emulsions. Spec Publ Roy Soc Chem 227:236-245.
18. Millqvist-Fureby A, Malmsten M, Bergenstahl B. 1999. Surface characterisation of freeze-dried protein/carbohydrate mixtures. Int J Pharm 191:103-114.
19. Millqvist-Fureby A, Malmsten M, Bergenstahl B. 1999. Spray-drying of trypsin - surface characterisation and activity preservation. Int J Pharm 188:243-253.
20. Akers MJ, Milton N, Nail SL. 1995. Glycine crystallization during freezing: The effects of salt form, pH, and ionic strength. Pharm Res 12:1457-1461.
21. Luand X, Pikal MJ. 2004. Freeze-drying of mannitol-trehalose-sodium chloride-based formulations: The impact of annealing on dry layer resistance to mass transfer and cake structure. Pharm Dev Technol 9:85-95.
22. Heller MC, Carpenter JF, Randolph TW. 1999. Conformational stability of lyophilized PEGylated proteins in a phase-separating system. J Pharm Sci 88:58-64.
23. Heller MC, Carpenter JF, Randolph TW. 1996. Effects of phase separating systems on lyophilized hemoglobin. J Pharm Sci 85:1358-1362.
24. Randolph TW. 1997. Phase separation of excipients during lyophilization: Effects on protein stability. J Pharm Sci 86:1198-1203.
25. Luand Q, Zografi G. 1998. Phase behavior of binary and ternary amorphous mixtures containing indomethacin, citric acid, and PVP. Pharm Res 15:1202-1206.
26. Izutsu K, Yoshioka S, Carpenter JF. 1996. Effects of sugars and polymers on crystallization of poly (ethylene glycol) in frozen solutions: Phase separation between incompatible polymers. Pharm Res 13:1393-1400.
27. Breen ED, Curley JG, Shire SJ. 2001. Effect of moisture on the stability of a lyophilized humanized monoclonal antibody formulation. Pharm Res 18:1345-1353.
28. Cleland JL, Lam X, Carpenter JF. 2001. A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody. J Pharm Sci 90:310-321.
29. Maury M, Murphy K, Lee G. 2005. Spray-drying of proteins: Effects of sorbitol and trehalose on aggregation and FT-IR amide I spectrum of an immunoglobulin G. Eur J Pharm Biopharm 59: 251-261.
30. Chang L, Shepherd D, Pikal MJ. 2005. Mechanism of protein stabilization by sugars during freeze-drying and storage: Native structure preservation, specific interaction, and/or immobilization in a glassy matrix? J Pharm Sci 94:1427-1444.
31. Chang L, Shepherd D, Pikal MJ. 2005. Effect of sorbitol and residual moisture on the stability of lyophilized antibodies: Implications for the mechanism of protein stabilization in the solid state. J Pharm Sci 94:1445-1455.
32. Abdul-Fattah A, Kalonia D, Pikal M. 2007. The challenge of drying method selection for protein pharmaceuticals: Product quality implications. J Pharm Sci 96:1886-1916.
33. Sane SU, Wong R, Hsu CC. 2004. Raman spectroscopic characterization of drying-induced structural changes in a therapeutic antibody: Correlating structural changes with long-term stability. J Pharm Sci 93:1005-1018.
34. Pearlmanand R, Bewley TA. 1993. Stability and characterization of human growth hormone. Pharm Biotechnol 5:1-58.
35. Bastirasand S, Robins A. 2000. Modified human growth hormone preparation and therapeutic use, Australia: Bresagen Ltd. Application: WO. p 20.
36. Larhammar H, Sjoeholm I, Wichman A. 1985. Comparative conformational analysis of human somatotropin and biosynthetic methionyl human somatotropin by spectroscopic titrations. Int J Pharm 23:13-23.
37. Franks F, Hatley RHM, Mathias SF. 1991. Materials science and the production of shelf-stable biologicals. Pharm Technol Int 3:24-34.
38. Schroederand AL, Schwarz HW. 1949. Low-temperature vacuum dehydration. Chem Eng Prog 45:370-376.
39. Bronshtein V. 1998. Preservation by foam formation, USA: Universal Preservation Technologies, Inc. Application: WO. p 13.
40. Bronshtein V. 2005. Preservation of biopharmaceuticals and vaccines by vaporization. PCT Int Appl. 53 p.
41. Abdul-Fattah A, Pikal M, Lechuga-Ballesteros D. 2005. Composition heterogeneity effects due to variation in processing and formulation of Methionyl-human Growth Hormone, AAPS National Biotechnology Conference, San Francisco, CA.
42. DePaz R, Dale D, Randolph T. 2002. Effects of drying methods and additives on the structure, function, and storage stability of subtilisin: Role of protein conformation and molecular mobility. Enzyme Microb Technol 31:765-774.
43. Dongand A, Caughey WS. 1994. Infrared methods for study of hemoglobin reactions and structures. Methods Enzymol 232:139-175.
44. Carpenter JF, Prestrelski SJ, Dong A. 1998. Application of infrared spectroscopy to development of stable lyophilized protein formulations. Eur J Pharm Biopharm 45:231-238.
45. Costantino HR, Carrasquillo KG, Griebenow K. 1998. Effect of excipients on the stability and structure of lyophilized recombinant human growth hormone. J Pharm Sci 87:1412-1420.
46. Izutsu K-I, Aoyagi N, Kojima S. 2004. Protection of protein secondary structure by saccharides of different molecular weights during freeze-drying. Chem Pharm Bull 52:199-203.
47. Kendrick BS, Dong A, Carpenter JF. 1996. Quantitation of the area of overlap between second-derivative amide I infrared spectra to determine the structural similarity of a protein in different states. J Pharm Sci 85:155-158.
48. Prestrelski SJ, Tedeschi N, Carpenter JF. 1993. Dehydration-induced conformational transitions in proteins and their inhibition by stabilizers. Biophys J 65:661-671.
49. Tripp BC, Magda JJ, Andrade JD. 1995. Adsorption of globular proteins at the air/water interface as measured via dynamic surface tension: Concentration dependence, mass-transfer considerations, and adsorption kinetics. J Colloid Interface Sci 173:16-27.
50. Katakam M, Bell LN, Banga AK. 1995. Effect of surfactants on the physical stability of recombinant human growth hormone. J Pharm Sci 84:713-716.
51. Pikal MJ, Shah S, Lang JE. 1983. Physical chemistry of freeze-drying: Measurement of sublimation rates for frozen aqueous solutions by a microbalance technique. J Pharm Sci 72:635-650.
52. Sladeand L, Levine H. 1991. Beyond water activity: Recent advances based on an alternative approach to the assessment of food quality and safety. CRC Crit Rev Food Sci Nutr 30:115-360.
53. Searles JA, Carpenter JF, Randolph TW. 2001. Annealing to optimize the primary drying rate, reduce freezing-induced drying rate heterogeneity, and determine Tg' in pharmaceutical lyophilization. J Pharm Sci 90:872-887.
54. Randolph TW, Searles JA. 2002. Freezing and annealing phenomena in lyophilization: Effects upon primary drying rate, morphology, and heterogeneity. Am Pharm Rev 5:40-46.
55. Yang TH, Dong A, Carpenter JF. 1999. Use of infrared spectroscopy to assess secondary structure of human growth hormone within biodegradable microspheres. J Pharm Sci 88:161-165.
56. Allison SD, Randolph TW, Carpenter JF. 1999. Hydrogen bonding between sugar and protein is responsible for inhibition of dehydration-induced protein unfolding. Arch Biochem Biophys 365:289-298.
57. Mumenthaler M, Hsu CC, Pearlman R. 1994. Feasibility study on spray-drying protein pharmaceuticals: Recombinant human growth hormone and tissue-type plasminogen activator. Pharm Res 11:12-20.
58. Maa Y-F, Nguyen P-AT, Hsu SW. 1998. Spray-drying of air-liquid interface-sensitive recombinant human growth hormone. J Pharm Sci 87:152-159.
59. Bam NB, Cleland JL, Randolph TW. 1998. Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions. J Pharm Sci 87:1554-1559.
60. Maaand Y-F, Hsu CC. 1997. Protein denaturation by combined effect of shear and air-liquid interface. Biotechnol Bioeng 54:503-512.
61. Tangand X, Pikal MJ. 2005. Measurement of the kinetics of protein unfolding in viscous systems and implications for protein stability in freeze-drying. Pharm Res 22:1176-1185.
62. Yoshioka S, Aso Y, Kojima S. 2001. Usefulness of the Kohlrausch-Williams- Watts stretched exponential function to describe protein aggregation in lyophilized formulations and the temperature dependence near the glass transition temperature. Pharm Res 18:256-260.
63. Pikaland MJ, Rigsbee DR. 1997. The stability of insulin in crystalline and amorphous solids: Observation of greater stability for the amorphous form. Pharm Res 14:1379-1387.
64. Riggin RM, Dorulla GK, Miner DJ. 1987. A reversed-phase high-performance liquid chromatographic method for characterization of biosynthetic human growth hormone. Anal Biochem 167:199-209.
65. Sarciaux J-M, Mansour S, Nail SL. 1999. Effects of buffer composition and processing conditions on aggregation of bovine IgG during freeze-drying. J Pharm Sci 88:1354-1361.
66. Colaço C, Sen S, Thangavelu M, Pinder S, Roser B. 1992. Extraordinary stability of enzymes dried in trehalose: Simplified molecular biology. Bio/Technology 10:1007-1011.
67. Roser B. 1991. Trehalose drying: A novel replacement for freeze-drying. BioPharm 4:47-53.
68. Lide DR. 2002. CRC Handbook of Chemistry and Physics. 83rd Edition. BocaRaton, FL: CRC Press.
69. Poirier-Brulez F, Roudaut G, Simatos D. 2006. Influence of sucrose and water content on molecular mobility in starch-based glasses as assessed through structure and secondary relaxation. Biopolymers 81:63-73.
70. Pikal MJ. 2004. Mechanisms of protein stabilization during freeze-drying and storage: The relative importance of thermodynamic stabilization and glassy state relaxation dynamics. In: Ray L, May J, editors. Drugs and the pharmaceutical sciences: Freeze-drying/lyophilization of pharmaceutical and biological products. Vol. 137, New York: Marcel Dekker. pp 63-107.
71. Abdul-Fattah A, Truong-Le V, Yee L, Nguyen L, Kalonia D, Cicerone MT, Pikal M. 2007. Drying induced variations in physico-chemical properties of amorphous pharmaceuticals and their impact on stability: stability of a monoclonal antibody. J Pharm Sci 96:1983-2008.
72. Abdul-Fattah AM, Truong-Le V, Yee L, Pan E, Ao Y, Kalonia D, Pikal M. 2007. Drying-induced variations in physico-chemical properties of amorphous pharmaceuticals and their impact on stability II: Stability of a vaccine. Pharm Res 24:715-727.
73. Elversson J, Millqvist-Fureby A, Elofsson U. 2003. Droplet and, particle size relationship and shell thickness of inhalable lactose particles during spray drying. J Pharm Sci 92:900-910.